Skip to main content

Table 3 Antimicrobial susceptibility of H. influenzae as classified by CLSI and EUCAST §

From: Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

Antimicrobial agenta(n° of strains) CLSI susceptibility breakpoint (mg/L) EUCAST susceptibility breakpoint(mg/L) CLSI %S EUCAST %S Type of discrepancyb
Ampicillin-sulbactam (223) 2 1 98.2 92.4 minor
Amoxicillin-clavulanate (47.030) 4 ≤2 99.7 98.4 minor
Cefaclor (28.338) 8 0.5 92.6 3.5 very major
Cefixime (7.403) 1 0.125 99.9 97.9 minor
Cefpodoxime (20.842) 2 0.25 99.9 96.7 minor
Cefuroxime axetil (94.671) 4 0.125 97.9 1.3 very major
Cefuroxime parenteral (94.671) 4 1 97.9 76.9 major
Cefotaxime (13.655) 2 0.125 99.6 99.7 -
Ceftriaxone (170) 2 0.125 100 96.5 minor
Cefepime (396) 2 0.25 100 91.7 minor
Ceftibuten (444) 2 1 98.4 97.1 minor
Meropenem non meningitis (6.511) 0.5 2 99.9 100 -
Imipenem (3.828) 4 2 98.9 97.4 minor
Ciprofloxacin (12.794) 1 0.5 99.7 99.6 -
Levofloxacin (22.880) 2 1 99.9 99.8 -
Moxifloxacin (14.177) 1 0.5 99.7 99.8 -
Ofloxacin (3.762) 2 0.5 100 99.9 -
Azithromycin (29.942) 4 0.125 99.3 1.2 very major
Clarithromycin (27.816) 8 1 82.9 1.5 very major
Telithromycin (5.382) 4 0.125 99.0 0.5 very major
Tetracycline (39.928) 2 1 97.7 96.8 -
  1. § CLSI [11] and EUCAST [13].
  2. aFor Ampicillin, Chloramphenicol, Ertapenem, Rifampin and Trimethoprim/sulfamethoxazole CLSI and EUCAST suggested the same susceptibility breakpoints.
  3. b Discrepancy as defined in the materials and methods section.